These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16629053)

  • 1. Oligonucleotide-mediated gene editing for neuromuscular disorders.
    Bertoni C
    Acta Myol; 2005 Dec; 24(3):194-201. PubMed ID: 16629053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides.
    Bertoni C
    Front Biosci; 2008 Jan; 13():517-27. PubMed ID: 17981565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strand bias in oligonucleotide-mediated dystrophin gene editing.
    Bertoni C; Morris GE; Rando TA
    Hum Mol Genet; 2005 Jan; 14(2):221-33. PubMed ID: 15563511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
    Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
    Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotide-mediated gene therapy for muscular dystrophies.
    Rando TA
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S55-60. PubMed ID: 12206797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
    Nik-Ahd F; Bertoni C
    Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic therapeutic approaches for Duchenne muscular dystrophy.
    Foster H; Popplewell L; Dickson G
    Hum Gene Ther; 2012 Jul; 23(7):676-87. PubMed ID: 22647146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Janssen PM; Montgomery CL; Coley BD; Chicoine LG; Clark KR; Mendell JR
    J Transl Med; 2007 Sep; 5():45. PubMed ID: 17892583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
    Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
    Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview on DMD exon skipping.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():97-116. PubMed ID: 22454057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotides, exon skipping and the dystrophin gene transcript.
    Wilton SD; Fletcher S
    Acta Myol; 2005 Dec; 24(3):222-9. PubMed ID: 16629057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for muscle disease.
    Miyagoe-Suzuki Y; Takeda S
    Exp Cell Res; 2010 Nov; 316(18):3087-92. PubMed ID: 20580709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-viral approaches for gene transfer.
    Wolff J; Lewis DL; Herweijer H; Hegge J; Hagstrom J
    Acta Myol; 2005 Dec; 24(3):202-8. PubMed ID: 16629054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue of dystrophin mRNA of Duchenne muscular dystrophy by inducing exon skipping.
    Matsuo M; Takeshima Y
    Acta Myol; 2005 Oct; 24(2):110-4. PubMed ID: 16550927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide.
    Bartlett RJ; Stockinger S; Denis MM; Bartlett WT; Inverardi L; Le TT; thi Man N; Morris GE; Bogan DJ; Metcalf-Bogan J; Kornegay JN
    Nat Biotechnol; 2000 Jun; 18(6):615-22. PubMed ID: 10835598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
    Matsuo M
    IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In utero delivery of oligodeoxynucleotides for gene correction.
    Cai L; Koppanati BM; Bertoni C; Clemens PR
    Methods Mol Biol; 2014; 1114():399-411. PubMed ID: 24557918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.